Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E A Emini

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|September 11, 1997
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapyR M Gulick, J W Mellors, D Havlir, et al.
Vaccine|September 13, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccineK A Bryant, R Frenck, A Gurtman, et al.
Nature|June 18, 1981
Primary structure, gene organization and polypeptide expression of poliovirus RNAN Kitamura, B L Semler, P G Rothberg, et al.
Journal of Virology|October 1, 1996
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolateA J Conley, J A Kessler, L J Boots, et al.
Annals of Internal Medicine|July 6, 2000
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudineR M Gulick, J W Mellors, D Havlir, et al.
JAMA|July 11, 1998
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-upR M Gulick, J W Mellors, D Havlir, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanesP E Finke, B Oates, S G Mills, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memoryAndrés de Roux, B Schmöle-Thoma, B Schmöele-Thoma, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Combinatorial synthesis of CCR5 antagonistsC A Willoughby, S C Berk, K G Rosauer, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|September 11, 1997
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapyR M Gulick, J W Mellors, D Havlir, et al.
Vaccine|September 13, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccineK A Bryant, R Frenck, A Gurtman, et al.
Nature|June 18, 1981
Primary structure, gene organization and polypeptide expression of poliovirus RNAN Kitamura, B L Semler, P G Rothberg, et al.
Journal of Virology|October 1, 1996
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolateA J Conley, J A Kessler, L J Boots, et al.
Annals of Internal Medicine|July 6, 2000
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudineR M Gulick, J W Mellors, D Havlir, et al.
JAMA|July 11, 1998
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-upR M Gulick, J W Mellors, D Havlir, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanesP E Finke, B Oates, S G Mills, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memoryAndrés de Roux, B Schmöle-Thoma, B Schmöele-Thoma, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Combinatorial synthesis of CCR5 antagonistsC A Willoughby, S C Berk, K G Rosauer, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Pageof 10